Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZYNE Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis Get Zynerba Pharmaceuticals alerts: Email Address About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsJovine Was Right in 2008—Will You Listen This Time?The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Get ZYNE alerts:Sign Up Key Stats Today's Range$1.26▼$1.3450-Day Range$1.21▼$1.3952-Week Range$0.25▼$1.40Volume862,700 shsAverage Volume515,333 shsMarket Capitalization$70.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Read More… Jovine Was Right in 2008—Will You Listen This Time? (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.Take these 4 steps today to protect your retirement NOW Receive ZYNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYNE Stock News HeadlinesFragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery PartnersJuly 31, 2024 | globenewswire.comHarmony Biosciences Reports Strong Third Quarter 2023 Financial ResultsOctober 31, 2023 | finance.yahoo.comNOTICE: You have until Tuesday, November 19thOn Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...September 28, 2024 | Behind the Markets (Ad)Why Shares of Harmony Bioscience Are Falling on FridayOctober 13, 2023 | fool.comNew Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder TherapiesOctober 11, 2023 | markets.businessinsider.comHARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINEOctober 11, 2023 | finance.yahoo.comImportant Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and InstructionsOctober 4, 2023 | finance.yahoo.com20 Countries With Highest Rate of EpilepsySeptember 29, 2023 | finance.yahoo.comSee More Headlines ZYNE Stock Analysis - Frequently Asked Questions How were Zynerba Pharmaceuticals' earnings last quarter? Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. When did Zynerba Pharmaceuticals IPO? Zynerba Pharmaceuticals (ZYNE) raised $42 million in an IPO on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers. What other stocks do shareholders of Zynerba Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/15/2023Today9/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ZYNE CUSIPN/A CIK1621443 Webwww.zynerba.com Phone(484) 581-7505FaxN/AEmployees25Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-90.03% Return on Assets-72.62% Debt Debt-to-Equity RatioN/A Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.29Miscellaneous Outstanding Shares53,939,000Free Float46,905,000Market Cap$70.12 million OptionableOptionable Beta1.32 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:ZYNE) was last updated on 9/28/2024 by MarketBeat.com Staff From Our Partners10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredThe Standard Oil of AI?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zynerba Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zynerba Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.